Resolutions from Sobi's Annual General Meeting
(Thomson Reuters ONE) -
The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM)
convened earlier today in Stockholm and voted in favour of the resolutions
proposed at the meeting, including:
Adoption of the profit and loss statements and balance sheet and discharge of
liability
The AGM adopted the income statements and the balance sheets and approved the
proposal to carry forward the retained profits of SEK 4,561,601,316 .
The board members and the chief executive officer were discharged from liability
for the financial year 2014.
Election of Board of Directors, remuneration to the Directors and election of
Auditor
The ordinary board members Adine Grate Axén, Annette Clancy, Matthew Gantz, Bo
Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell
were re-elected and Bo Jesper Hansen was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the nomination
committee's proposal.
Ernst & Young was elected as auditor of Sobi until the end of the annual general
meeting 2016.
Principles for remuneration for the management, long-term incentive program and
transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.
The AGM also approved the Board's proposal regarding the implementation of a
long-term incentive program, and hedging arrangements in respect of the program
including a directed issue of no more than 1,036,856 series C shares,
authorisation for the Board to decide on a repurchase of all issued series C
shares and transfers of no more than 1,630,976 own common shares to program
participants.
The Board's proposal regarding transfer of no more than 193,233 own common
shares on the stock exchange for the purpose of covering certain payments,
mainly social security contributions, that may occur in relation to the Share
Program 2012, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to
www.sobi.com.
- - -
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
The information was released for public distribution on June 30, 2015 at 16.15
p.m. CET.
025e_AGM resolutions:
http://hugin.info/134557/R/1933006/695647.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#1933006]
Unternehmensinformation / Kurzprofil:
Datum: 30.06.2015 - 16:16 Uhr
Sprache: Deutsch
News-ID 404021
Anzahl Zeichen: 4299
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Resolutions from Sobi's Annual General Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
